MoonLake Immunotherapeutics Cash Flow Statement
NASDAQ: MLTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
10.82+0.24 (+2.27%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MoonLake Immunotherapeutics free cash flow
In fiscal 2025, MoonLake Immunotherapeutics generated -$196.0 million of operating cash flow and spent $35,000 on capital expenditures. That left free cash flow of -$196.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
MoonLake Immunotherapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 |
|---|---|---|---|---|---|
| Net Income | -230.32M | -121.24M | -44.08M | -64.51M | -4.54M |
| Net Income growth (YoY) | — | — | — | — | — |
| Depreciation & Amortization | 2.62M | 1.39M | 370.00K | 164.78K | — |
| Stock-Based Compensation | 12.90M | 7.28M | 7.11M | 9.65M | — |
| Change in Working Capital | 20.56M | 7.16M | 1.58M | -1.31M | 3.80M |
| Operating Cash Flow | -196.01M | -116.59M | -42.78M | -55.89M | -611.07K |
| Capital Expenditures | -35.00K | -520.00K | -284.00K | -16.01K | — |
| Investing Cash Flow | 202.99M | -205.60M | -25.18M | -32.34M | — |
| Share Repurchases | — | -50 | 0 | 0 | — |
| Debt Issued | 73.02M | 0 | 0 | — | — |
| Financing Cash Flow | 146.00M | 51.31M | 479.70M | 119.69M | -58.06K |
| Net Change in Cash | 154.09M | -270.74M | 411.66M | 31.47M | -669.13K |
| Free Cash Flow | -196.04M | -117.11M | -43.06M | -55.91M | -611.07K |
This table shows 5 annual periods of MoonLake Immunotherapeutics's cash flow statement, from FY 2025 back to FY 2021, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MLTX's reporting calendar. What is a cash flow statement?